The global cancer market has just seen a period of rapid growth. Between 2003 and 2005, global sales for cancer treating drugs increased by 40% and now account for more than eight percent of total global pharmaceutical sales. Although growth rates for this market will slow due to generic competition the market is predicted to expand to $85.3 billion by 2010 equivalent to CAGR of 11.1%
Cancer Market Trends, 2006-2010 - Key market forecasts and growth opportunities provides a superb trend analysis of the growing cancer market.
This comprehensive report delivers market forecasts and overviews to help inform you in your pharmaceutical business decision-making.
Key findings from the report include:
The worldwide incidence of new cancer patients is forecast to increase from 4.2 million cases in the major cancer markets in 2005 to 4.6 million in 2010.
The cancer having the greatest impact on the population in the leading pharmaceutical markets is cancer of the trachea, bronchus and lung.
Global cancer market growth of 16.5% in 2005 was primarily driven by growth of 41.2% in innovative sales.
The worldwide cancer market is dominated by the selected adjuncts drug class with a market share of 38.3%, followed chemotherapeutics, innovatives and then hormonals.
Five of the top 10 leading cancer products in 2005 were selected adjuncts (Eprex/ Procrit, Aranesp, Epogen, Neulasta and NeoRecormon/ Epogin), two were innovatives (Rituxan/ MabThera and Gleevec/ Glivec), two were chemotherapeutics (Taxotere and Eloxatin) and one was a hormonal (Lupron).
14 pharmaceutical companies were identified as having generated cancer sales in excess of US$1 billion in 2005.
This report provides key information needed in your business including:
Sales forecast for top ten companies providing cancer treatment medicines.
Analysis of leading cancer products likely to loose patent protection in the next ten years.
Sales forecasts to 2010 for the top ten cancer medicines and forecasts by drug class.
Overview of disease incidence, areas of growth and breakdown of disease burden and mortality.
Breakdown of the major market trends and business opportunities
Use This Report To:
Benchmark your company’s portfolio against market trends and forecasts to plan better for greater profitability.
Spot areas of pharmaceutical market growth and good opportunities for delivering successful sales growth
Support your internal planning processes by using an external perspective founded on detailed analysis and transparent market forecasts.
The 111 page publication contains 49 Figures and 43 Tables to help you make sense of the wealth of data. This report will be of particular use to those involved in:
corporate planning,
sales and marketing,
portfolio management, and,
market forecasting.
The report is divided into five key sections. Chapters 2-5 present historical trends for key disease markets, key drug classes, key products and key companies. The final report chapter outlines future cancer market trends and major growth opportunities. The data and analysis contained within the report are comprehensive, consistent and up-to-date and thus provide a single-point of reference for understanding cancer market trends.
(0 items)
